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Drug-induced liver injury (DILI) is a major cause of failed drug development, withdrawal and restricted
usage. Therefore screening assays which aid selection of candidate drugs with reduced propensity to
cause DILI are required. We have investigated the toxicity of 144 drugs, 108 of which caused DILI, using
assays identiﬁed in the literature as having some predictivity for hepatotoxicity. The validated assays uti-
lised either HepG2 cells, HepG2 cells in the presence of rat S9 fraction or isolated human hepatocytes. All
parameters were quantiﬁed by multiplexed and automated high content ﬂuorescence microscopy, at
appropriate time points after compound administration (4, 24 or 48 h). The individual endpoint which
identiﬁed drugs that caused DILI with greatest precision was maximal fold induction in CM-H2DFFDA
staining in hepatocytes after 24 h (41% sensitivity, 86% speciﬁcity). However, hierarchical clustering anal-
ysis of all endpoints provided the most sensitive identiﬁcation of drugs which caused DILI (58% sensitiv-
ity, 75% speciﬁcity). We conclude that multi-parametric high content cell toxicity assays can enable
in vitro detection of drugs that have high propensity to cause DILI in vivo but that many DILI compounds
exhibit few in vitro signals when evaluated using these assays.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Drug induced liver injury (DILI) in humans is caused by many
hundreds of widely prescribed drugs and is a leading cause of
failed drug development, failed registration, withdrawal of li-
censed drugs and cautionary labeling which restricts drug usage
(Kaplowitz, 2005; Kola and Landis, 2004). The underlying mecha-
nisms are complex and include both drug related and patient re-
lated processes (Thompson et al., 2011). Drug related properties
determine whether or not DILI arises in the human population,while patient related factors inﬂuence whether or not individual
drug treated patients sustain liver injury. Many of the drug related
processes which cause DILI can be studied using in vitro assays. Use
of such assays as predictive toxicology screens during drug discov-
ery, when there is chemical choice, therefore could aid selection of
compounds which have minimal propensity to cause DILI.
Numerous in vitro approaches have been described which could
be suitable for this purpose. Multi-parametric ﬂuorescent imaging
is an especially attractive option since it enables simultaneous
investigation of a variety of endpoints and was used by O’Brien
et al. (2006) to investigate the toxicity of 243 compounds to HepG2
cells. The parameters assessed, and the ﬂuorescent probes used,
were: calcium content, Fluo-4 AM; mitochondrial membrane po-
tential, TMRM; plasma membrane permeability, TOTO-3; and
DNA content, Hoechst 33342 (O’Brien et al., 2006). When the data
were adjusted to take account of the reported maximum human
plasma concentrations of the drugs, a speciﬁcity of 98% and a sen-
sitivity of 93% for detection of compounds that cause DILI was ob-
served. However, HepG2 cells express low levels of Phase I and
Phase II drug metabolising enzymes when compared with isolated
human primary hepatocytes (HPH) (Riley and Workman, 1992;
Wilkening et al., 2003). These enzymes play key roles in metabolic
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formation of chemically reactive metabolites (Kaplowitz, 2005;
Pirmohamed et al., 1996). Therefore in vitro toxicity studies under-
taken using HepG2 cells can be expected to underestimate metab-
olite mediated toxicity and might also over-estimate the
signiﬁcance of cell toxicity caused by drugs which are rapidly
metabolised in hepatocytes. In a subsequent study, toxicity of a
range of drugs to HepG2 cells which were supplemented with rat
liver S9, which contains many different Phase 1 and Phase 2 en-
zyme activities, was studied (Otto et al., 2008). This approach re-
vealed potentiated HepG2 cell toxicity caused by compounds
which are metabolised to reactive intermediates, for example
cyclophosphamide and diclofenac, in the presence of S9.
Isolated HPH retain a broad complement of Phase I and II metab-
olism enzymes when cultured under suitable conditions (Hamilton
et al., 2001; LeCluyse et al., 2000; LeCluyse, 2001). The utility of cul-
tured HPH for in vitro drug toxicity testing was explored by Xu et al.
(2008), who expanded the range of cellular phenotypes measured
by O’Brien et al. (2006) and assessed generation of reactive oxygen
species, glutathione content, mitochondrialmembrane potential, li-
pid accumulation, nuclear area and cell number (O’Brien et al.,
2006; Xu et al., 2008). Data obtained using >300 drugs revealed that
this approach discriminated between drugs that caused DILI and
drugs that did not cause DILI with a speciﬁcity of 95–100% and a
sensitivity of 50–60%. This observed DILI sensitivity is notably low-
er than that reported by O’Brien et al. (2006). Widespread use of
HPH in toxicity studies has been limited by the restricted availabil-
ity and high expense of these cells and by the marked variation that
may occur between cells from different human donors (Guillouzo,
1998). However, cryopreserved adherent human hepatocytes
which exhibit high viability and good retention of metabolic capa-
bility have become available recently from commercial sources
which could be suitable for use in in vitro toxicity studies (Moeller
et al., 2012). These are available from single donors or as pooled
batches, which minimise donor to donor variability.
The aim of the present work was to investigate the association
between DILI and toxicities of a broad range of drugs to HepG2
cells, HepG2 cells cultured in the presence of rat S9 fraction or
cryopreserved HPH. Cell toxicity was assessed using multiple end-
points, which included multi-parametric high content ﬂuorescent
cell imaging. All of the cell models and assay endpoints were vali-
dated to ensure that signal windows were sufﬁcient for screening
and that there were appropriate responses to positive and negative
control compounds. To explore the potential predictive toxicity va-
lue of the three in vitro assay systems, data were obtained using
144 pharmaceuticals, 108 of which have been reported to cause
clinically concerning DILI in humans.
2. Materials and methods
2.1. Materials
Human primary hepatocytes (HPH) from a single donor were
obtained from Invitrogen Life Sciences (San Diego, CA). Hepatocyte
basal medium (HBM™) and medium supplements (HCM™ Single-
Quots™) were obtained from LONZA (Basel, Switzerland). Human
hepatocellular carcinoma cell line (HepG2) was obtained from
the American Tissue Culture Collection (Manassas,VA). HepG2 cul-
ture medium (RPMI1640 without L-glutamine, L-alanyl-L-Gluta-
mine and sodium pyruvate) were obtained from Cellgro, Inc.
(Manassas,VA). Fetal bovine serum (FBS) was obtained from Ther-
mo Fisher Scientiﬁc (Waltham, MA). S9 fractions from Aroclor-
treated rats (rS9) were obtained from Molecular Toxicology
(Boone, NC) and the NADPH regenerating system was from BD Bio-
sciences (Billerica, MA). Fluorescent probes, 40,6-diamidino-2-
phenylindole (DAPI), LipidTox™ Green Phospholipid StainH34350, LipidTox™ Red Neutral Lipid Stain H34476, Tetramethyl-
rhodamine (TMRE), and 6-carboxy-20,70-dichlorodihydroﬂuoresce-
in diacetate (CM-H2DFFDA) were obtained from Invitrogen Life
Sciences (San Diego, CA) and the nuclear stain Hoechst 33342 from
Thermo Fisher Scientiﬁc (Waltham, MA). Primary antibodies for
activated caspase-3, anti-phospho-Histone-H3 and anti-HSP 70/
72 were obtained from Cell Technology (Marlborough, MA), Abcam
(Cambridge, MA) and Enzo Life Sciences (Farmingdale, NY), respec-
tively. Secondary Alexa Fluor antibodies 488, 594 and 647 were ob-
tained from Invitrogen Life Sciences (San Diego, CA). Other
chemicals and drugs used for assay optimization were obtained
from Sigma Aldrich (St. Louis, MO), Tocris Biosciences (Bristol, Uni-
ted Kingdom) or Sequoia Research Products (Pangbourne, United
Kingdom). The 144 DILI and non-DILI compounds evaluated in
the screen assays were obtained from Compound Management
(AstraZeneca R&D, Macclesﬁeld, UK). Para-formaldehyde was ob-
tained from Electron Microscopy Sciences (Hatﬁeld, PA), BD Bio-
Coat Cellware Collagen Type I 384-well Microplates were
obtained from BD Biosciences (Billerica, MA), 384-well TC-Treated
Polystyrene Microplates from Corning Life Sciences (Tewksbury,
MA) and Echo Qualiﬁed 384-Well Polypropylene Microplates
from LabCyte Inc. (Sunnyvale, CA). DMSO was obtained from Sigma
Aldrich (St. Louis, MO).
2.2. Cell plating
Cryopreserved HPH were thawed in hepatocyte culture medium
containing supplements and growth factors (HBM™,HCMSingleQu-
ots™) and viable cells were isolated by Percoll density gradient cen-
trifugation. Cells were sedimented by centrifugation (70g, 3 min,
25 C) and the cell pellet was resuspended in 40 ml of an isotonic
NaCl/Percoll solution (1 part 9% NaCl and 9 parts Percoll), then cen-
trifuged (70g, 10 min, 25 C) once again. The supernatant was dis-
carded and the pelleted hepatocytes were resuspended in HCM,
then seeded into 384-well collagen type I coated optical plates at
12,000 viable cells per well in 40 ll HCM using a Multidrop Combi
(Thermo Scientiﬁc, Rockford, IL). The plated cells were incubated
in a humidiﬁed atmosphere of 5% CO2 at 37 C for 24 h and then
themediumwas replacedwith 30 ll of fresh HCM. After incubation
in 5% CO2 at 37 C for a further 24 h, the medium was exchanged a
second time immediately prior to compound addition. HepG2 cells
from previously banked stocks, which had been stored in liquid
nitrogen vapour phase, were thawed in a 37 Cwater bath andwere
cultured in complete growth medium (RPMI1640 medium supple-
mented with 10% FBS, 2 mM L-Alanyl-L-Glutamine and 1 mM So-
dium Pyruvate) in a humidiﬁed atmosphere of 5% CO2 at 37 C.
The HepG2 cells were passaged once prior to plating and then were
seeded into 384-well TC-Treated Polystyrene Microplates, in 60 ll
complete growthmediumperwell. To ensure optimal cell coverage,
the seeding densities were: 6000 viable cells per well when cells
were evaluated 4 h after compound addition; 4500 viable cells per
well when cells were evaluated at 24 h after compound addition;
and 3000 viable cells per well in the experiments undertaken with
orwithout S9. Evaluation of phospholipid and neutral lipid accumu-
lationwas undertaken usingHepG2 cells whichwere passaged once
and then seeded into 384-well collagen type I coated optical plates
at a density of 3,600 viable cells per well in 30 ll complete growth
medium. Plated HPHs and HepG2 cells were incubated in a humid-
iﬁed atmosphere of 5% CO2 at 37 C prior to and for the duration of
test compound incubation.
2.3. Test compound administration
Compounds were solubilized at 200 times the highest test con-
centration in 100% DMSO. Final compound concentrations used for
the assay optimization ranged from 1 to 500 lM and from 1 to
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serially diluted 3.16-fold over 10 concentrations in 100% DMSO
from the highest test concentration and the diluted solutions were
transferred to Echo Qualiﬁed 384-Well Polypropylene Micro-
plates using a Biomek Fx. Each compound concentration was
tested in triplicate. When test compounds were evaluated in the
screen, each compound plate included a control compound rele-
vant to the cell model and assay endpoint, 7 test compounds and
DMSO treated vehicle control wells. Compounds were added to as-
say plates using the LabCyte 550 Echo acoustic liquid delivery
system (LabCyte, Sunnyvale, CA). The ﬁnal concentration of DMSO
in all assays was 0.5% (v/v).
When evaluating cell toxicity caused by the 144 tested drugs,
each compound was tested in triplicate in blinded experiments
which used 10-point half-log concentration response curves. Refer-
ence compound IC50/EC50 data were included on each test plate to
ensure assay validity.
2.4. TMRE and CM-H2DFFDA assays
After treatment of cells with test compounds for 4 h or 24 h, the
mediumwas removed by aspiration and was replaced with 50 ll of
Hank’s Balance Salt Solution which contained Hoechst 33342
(10 lg/ml), CM-H2DFFDA (5 lM) and TMRE (1 lM). After incuba-
tion of the cells for a further 30 min at 37 C, live cell imaging
was undertaken. After the imaging, the 24 h assay plates with
HepG2 cells and HPH were washed 1 and 3 times, respectively,
with 75 ll per well of PBS using a plate washer (ELx 405 Select,
BIO-TEK, Winooski, VT), were ﬁxed for 15 min at room tempera-
ture in 90 ll of 3.2% paraformaldehyde immunolabelled and then
analysed.
2.5. Immunolabeling of activated caspase-3, phosphorylated histone-
H3 and HSP 70/72 assays
Cellswereﬁxed at room temperature in 90 ll of 3.2%paraformal-
dehyde for 15 min, blocked for 15 min in 80 ll of buffer (TBS NaN3,
0.25% BSA, 0.25% goat serum, 0.05% Triton X-100) and then incu-
bated for 30 min with 50 ll of antibody buffer (PBS/NaN3, 0.25%
BSA, 0.05% Triton X-100) which contained rabbit anti-activated cas-
pase-3 antiserum diluted 1:200 and either mouse anti-phospho-
Histone-H3 antiserum diluted 1:1000, or mouse anti-HSP70/72
antiserum diluted 1:100. The plates were then washed twice with
75 ll of PBS/NaN3 per well, using the ELx 405 Select plate washer,
and incubated for 30 min with 50 ll of the same antibody buffer
which contained Alexa Fluor 488 goat anti-rabbit IgG (2 lg/ml)
and Alexa Fluor 594 goat anti-mouse IgG (2 lg/ml). The plates were
washed twice with 75 ll of PBS/NaN3 per well using the ELx 405 Se-
lect plate washer and then stained with DAPI (1 lg/ml) diluted in
PBS/NaN3. Immunolabelling of HepG2 andHPH cell plates thatwere
ﬁxed after live imaging was undertaken in the manner described
above using anti-activated caspase-3 primary antiserum and Alexa
Fluor 647 goat anti-rabbit IgG (2 lg/ml) secondary antiserum, then
re-staining of nuclei with DAPI.
2.6. Phospholipid (PLD) and neutral lipid accumulation assays
Twenty-four hours after plating of HepG2 cells, 20 ll of Lipid-
Tox™ Green Phospholipid stain diluted 1:800 in complete growth
medium was added to the cells, which then were immediately
treated with test compound. After incubation for an additional
48 h, the cells were ﬁxed for 15 min at room temperature in
80 ll of 3.2% paraformaldehyde, washed twice with 75 ll of PBS/
NaN3 per well using the ELx 405 Select plate washer and thenstained with 50 ll of PBS/NaN3 which contained LipidTox™ Red
Neutral Lipid Stain diluted 1:1000 and DAPI nuclear dye (1 lg/ml).
2.7. HepG2 S9 treatment
HepG2 cells were thawed and cultured as described previously.
The culture medium was replaced with 50 ll complete growth
medium containing rS9 (0.5 mg/ml) with supplementation with
an NADPH regeneration system (Solution A NADP + Glc-6-PO4 di-
luted 1:20 and solution B G6PDH diluted 1:100) immediately be-
fore addition of test compound. After incubation for 4 h and 24 h,
the medium was exchanged with fresh complete growth medium.
Cells that were exposed to test compound for 4 h treatment were
incubated for a total of 48 h before ﬁxation, while cells which were
exposed to test compound for 24 h compound treatment were
incubated for a total of 48 or 72 h before ﬁxation. Cells were ﬁxed
at room temperature in 90 ll of 3.2% paraformaldehyde. When
HepG2 cells were not treated with rS9, the medium was only ex-
changed at the end of the 4 and 24 h compound treatment incuba-
tions. These cell plates were incubated for a total of 48 h prior to
being ﬁxed as described above. The assay endpoints evaluated in
these experiments were activated caspase-3 multiplexed either
with phosphorylated Histone-H3 or HSP 70/72.
2.8. HCS image acquisition and analysis
Automated ﬂuorescence microscopy was carried out using a GE
Healthcare IN Cell Analyzer 1000. Images were collected using a 4X
objective. The image acquisition parameters were based on opti-
mal excitation and emission wavelengths of the multiplexed ﬂuo-
rescence probes. Images were obtained in channel 1 for nuclear
probes Hoechst 33342 and DAPI (360/40 ex and 460/40 em), chan-
nel 2 for CM-H2DFFDA, anti-activated caspase-3 antiserum, and
phospholipids (492/18 ex and 535/50 em), and channel 3 for TMRE,
anti-phospho-Histone H3 antiserum, anti-HSP 70/72 antiserum,
and neutral lipid dye (575/15 ex and 628/40 em). Secondary Alexa
Fluor antisera 488 (goat anti rabbit IgG) and 594 (goat anti mouse
IgG) were used to detect the primary antibodies in channels 2 and
3, respectively. When the HPHs and HepG2 live dye plates were
stained for activated caspase-3, this signal was imaged in the Cy5
channel (620/60 ex and 700/75 em) using the Alexa Fluor 647 goat
anti rabbit IgG secondary antiserum for detection of the anti-acti-
vated caspase-3 primary antibody, in order to avoid overlap with
the TMRE dye signal. For all HCS assays, twelve bit tiff images were
acquired with InCell Analyzer 1000 3.2 and analyzed with Devel-
oper Toolbox 1.6 software.
Proliferation of HepG2 cells was quantiﬁed by measurement of
the intensity of the signal of the incorporated nuclear dye. To quan-
tify cell proliferation, the data were transformed to percent of con-
trol (POC) using the formula:
POC ¼ relative cell count compound well
relative cell count vehicle wells
 100
For the HPH, which do not proliferate when cultured, the signal de-
ﬁned by nuclear segmentation of the incorporated nuclear dye was
used to quantify the number of attached live cells. To determine
the POC after exposure of the cells to test compounds, the live cell
data output was transformed using the same formula. The output
of each biomarker was expressed as the fold change when com-
pared with cells exposed to 0.5% DMSO vehicle. EC50 and IC50 val-
ues, which represent the concentrations at which 50% of the
maximum observed stimulatory effect or a 50% reduction in the
control signal was observed, respectively, were calculated using
nonlinear regression to ﬁt data to the dose–response, one-site mod-
el where:
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with y being the POC, A being the bottom of the curve (or min y va-
lue), B being the top of the curve (or max y value), C being the
inﬂection point EC50 and IC50 when both top and bottom of curve
are locked to 100 and 0 respectively, x being the molar concentra-
tion and D being the slope of the curve. Curve-ﬁtting, EC50/IC50 cal-
culations and report generation were performed using a custom
data reduction engine and MathIQ based software (AIM).
2.9. Statistical analysis of drug screening data
When screening the 144 drugs for in vitro toxicity, data on test
plates were considered valid when the reference compound IC50 or
EC50 values were within 3-fold of the pre-determined values. In or-
der to exclude data obtained that could not be attributed to cell
exposure to the drugs, in these experiments in vitro assay signals
were deﬁned as values that differed from the corresponding vehi-
cle control value by at least 6 times the standard deviation of the
control value.
The predictive power of each individual assay for DILI was as-
sessed using six different statistics: Accuracy (Acc, Eq. (1)), sensi-
tivity (Sens, Eq. (2)), speciﬁcity (Spec. Eq. (3)), Positive Prediction
Rate (PPR, Eq. (4)), Negative Prediction Rate (NPR, Eq. (5)) and Mat-
thews correlation coefﬁcient (MCC, Eq. (6)). An in vitro assay signal
was deﬁned as an endpoint value observed following cell exposure
to a test compound that differed from the corresponding vehicle
control value by at least 6 times the standard deviation of the con-
trol value. When a signal was observed with a drug that caused
DILI, this was classiﬁed as a true positive (TP), while the absence
of a signal with such a drug was classiﬁed as a false negative
(FN). Similarly, a signal caused by a drug not associated with DILI
was classiﬁed as a false positive (FP) and an absence of a signal
caused by such a drug was classiﬁed as a true negative (TN).
Acc ¼ ðTPþ TNÞðTPþ TNþ FPþ FNÞ ð1Þ
Sens ¼ TPðTPþ FNÞ ð2Þ
Spec ¼ TNðTNþ FPÞ ð3Þ
PPR ¼ TPðTPþ FPÞ ð4Þ
NPR ¼ TNðTNþ FNÞ ð5Þ
MCC ¼ ðTP  TN FP  FNÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðTPþ FPÞ  ðTPþ FNÞ  ðTNþ FPÞ  ðTNþ FNÞp ð6Þ
To investigate if any of the assays performed better in combination
than when analysed alone, the data were clustered using Ward
clustering with no standardization of data within JMP10.0. 7.Table 1
Criteria used to assign drugs to DILI categories.
DILI category (number of drugs) Criteria
1 (n = 30) Severe DILI: withdrawn or black b
2 (n = 35) High concern DILI: evidence of ac
3 (n = 43) DILI reports: symptomatic liver in
4 (n = 14) Transaminitis: elevated serum pa
5 (n = 22) No liver signalsHierarchical clustering is a computational method that consecu-
tively joins compounds with similar observations. The resulting tree
will have compounds that share activity/inactivity close to each
other, and far from compounds with different activity proﬁles. It
is an unsupervised learning method in that it does not take DILI
activity in to consideration when clustering compounds.
3. Results
3.1. DILI categorization of pharmaceuticals
The 144 drugs evaluated for toxicity in vitro were each assigned
to one of ﬁve categories, which summarised data on the severity
and clinical impact of DILI observed in patients that was extracted
from the peer reviewed scientiﬁc literature and from data con-
tained in product labels. The criteria used in the categorisation
are summarised in Table 1 and details of the drugs and their cate-
gories are listed in Supplementary Table 1. Thirty drugs have been
withdrawn from clinical use due to DILI, or have been given Black
Box warnings for DILI in the US product labels, and were catego-
rized as ‘‘Severe DILI’’. Thirty-ﬁve drugs have been associated with
acute liver failure in humans, but have not beenwithdrawn or given
DILI Black Box warnings, and were categorized as ‘‘High DILI Con-
cern’’. Forty-three drugs have been reported to cause symptomatic
liver injury, but not liver failure, and were categorized as ‘‘DILI Re-
ports’’. Fourteen drugs have been associated with raised serum lev-
els of alanine aminotransferase and other enzymes indicative of
drug induced liver dysfunction, but have not been reported to cause
symptomatic DILI, and were categorized as ‘‘Transaminitis’’. The
remaining 22 drugs have not been associated with evidence of liver
dysfunction and were categorized as ‘‘No Liver Signals’’. Recently,
77 of the 144 drugs have been assigned to one of three DILI concern
classes (High, Low or No Concern) by other investigators, who con-
sidered the clinical severity of DILI reported in the clinic and label-
ling approved by US FDA (Chen et al., 2011). This information is
summarised in Supplementary data Table 1 as ‘‘LTKB class’’.
3.2. Evaluation of the multiparametric imaging assays in HepG2 cells
and HPH
Live cell assay endpoints were evaluated in both HepG2 cells
and HPH following 4 or 24 h compound exposure. The parameters
studied were compound induced alterations in cell count, ROS gen-
eration (CM-H2DFFDA) and mitochondrial membrane potential
(TMRE). Exposure to carbonyl cyanide m-chlorophenyl hydrazone
(CCCP), which uncouples mitochondrial respiration (Heytler and
Prichard, 1962) caused marked and potent reductions in TMRE
intensity and elevated CM-H2DFFDA staining in HepG2 cells and
HPH. Representative images are shown in Fig. 1a, 1–2, and b, 1–
2. The live cell assays were repeated in both cells types using 7
additional assay validation compounds (chlorpromazine, ﬂutam-
ide, menadione, metformin, nefazodone, nimesulide and paclit-
axel) at 4 and 24 h post-dosing. These results are summarised in
Supplementary data Table 2. Since quite variable patterns of com-
pound and time dependent effects were observed, subsequent
investigations of the effects of test compounds on cell count, ROSox warning due to hepatotoxicity
ute liver failure
jury, but not acute liver failure
rameters indicating liver dysfunction, but symptomatic liver injury not reported
0.5% DMSO Vehicle Compound Treated
1. Nuclear (Hoechst – blue) / 
ROS (H2DFFDA - red) CCCP, 4 h treatment
2. Nuclear (Hoechst – blue) /
Mitochondrial Damage CCCP, 24 h treatment
(TMRE - green)
3. Nuclear (DAPI – blue) /
Apoptosis (Anti-activated Caspase 3) Geldanamycin, 24 h treatment
4. Nuclear (DAPI – blue) / 
Geldanamycin, 24 h treatmentCellular Stress 
(Anti-HSP70/72- green)
5. Nuclear (DAPI – blue) / 
Astemizole, 48 h treattmentPhospholipidosis
(phospholipid dye- green)
6. Nuclear (DAPI – blue) / 
Lipid accumulation Astemizole, 48 h treatment
(neutral lipid dye- red)
7. Nuclear (DAPI – blue) /Mitosis Cyclophosphamide, 
(Anti-phospho-Histone -H3 – green) 24 h treatment
0.5% DMSO Vehicle Compound Treated
1. Nuclear (Hoechst – blue) / ROS CCCP, 4 h treatment(H2DFFDA - red)
2. Nuclear (Hoechst – blue) /
Mitochondrial Damage (TMRE - CCCP, 24 h treatment
green)
(a)
(b)
Fig. 1. (a) Representative high content images from HepG2 cells treated with: (a) vehicle (0.5% DMSO); or (b) CCCP, geldanamycin, astemizole or cyclophosphamide. The data
obtained with cyclophosphamide and the associated vehicle data were from incubations undertaken with rat S9 + NADPH; the other data were obtained in the absence of rat
S9 or NADPH. Images (4X magniﬁcation) were obtained from the same ﬁeld of cells using different ﬁlters, to detect: 1. nuclei/ROS (Hoechst-blue/H2DFFDA-red); 2. nuclei/
mitochondrial damage (Hoechst-blue/TMRE-green); 3. nuclei/apoptosis (DAPI-blue/anti-activated caspase-3-red); 4. nuclei/cellular stress (DAPI-blue/anti-HSP70/72-green);
5. nuclei/phospholipidosis (DAPI-blue/phospholipids-green); 6. nuclei/lipid accumulation (DAPI-blue/neutral lipids-red); 7. nuclei//mitosis (DAPI-blue/anti-phospho-
Histone-H3-green). (b) Representative high content images from HPHs treated with: (a) vehicle (0.5% DMSO); or (b) CCCP. Images (4X magniﬁcation) were obtained from the
same ﬁeld of cells using different ﬁlters to detect: 1. nuclei/ROS (Hoechst-blue/H2DFFDA-red); 2. nuclei/mitochondrial damage (Hoechst-blue/TMRE-green). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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cells to test compounds for both 4 and 24 h.
Additionally, several ﬁxed cell endpoints were also investigated
in HepG2 cells, namely, activated caspase-3 expression (apoptosis),
expression of the cell stress proteins HSP70/72, cell count and accu-
mulation of phospholipid (PLD) and neutral lipids. Representative
images from the exposure of HepG2 cells and HPH to 17-(allylami-
no)-17-demethoxygeldanamycin (geldanamycin), a pro-apoptotic
compound (Lee et al., 2012), and astemizole, an inducer of phospho-
lipidosis (Muehlbacher et al., 2012), are shown in Fig. 1a, 3–4 and
5–6. Exposure of the cells to geldanamycin for 24 or 48 h resulted
in markedly increased levels of expression of activated caspase-3
and HSP70/72. The magnitude of induction of activated caspase-3
and HSP70/72 was greatest at 24 h (Supplementary data Table 3).
When HepG2 cells were exposed to astemizole, marked increases
in PLD and neutral lipid were evident after 48 hwhichwere not evi-
dent when cells were exposed to acetaminophen (Supplementary
data Table 4). The time point of 48 h was used in subsequent
evaluations of the effect of test compounds on PLD and lipid
accumulation.3.3. Evaluation of ﬁxed cell endpoints in the presence of rat S9 fraction
To assess whether inclusion of rS9 could enable investigation of
metabolite mediated toxicity to HepG2 cells, validation experi-
ments were undertaken with cyclophosphamide, a compound
known to be metabolised by P450s to a cytotoxic metabolite (Otto
et al., 2008). The endpoints assessed were cell count, expression of
activated caspase-3 and expression of phospho-Histone-H3.
Marked reductions in cell count and increases in expression of acti-
vated caspase-3 and phospho-Histone-H3 (indicating G1/S cell cy-
cle block (Preuss et al., 2003) were only observed when the rS9
incubations with cyclophosphamide were supplemented with the
P450 co-factor NADPH (Fig. 2, representative image Fig. 1a, 7). Sim-
ilar effects on cell count were observed in cells exposed to cyclo-
phosphamide/rS9/NADPH for 4 or 24 h; however, the magnitude
and potency of induction of activated caspase-3 and the potency
of phospho-Histone-H3 induction were increased markedly at
the 24 h time interval (Supplementary data Table 5).Fig. 2. Cytotoxicity in HepG2 cells exposed to increasing concentrations of cyclophospha
and e) in the presence of rS9 only; (c and f) in the presence of rS9/NADPH. Cytotoxicity
staining for cell proliferation (DAPI), apoptosis (anti-activated caspase-3), and mitosis (a
wells)/cell count (vehicle control wells)  100. Apoptosis and mitosis data are expressed
the mean ± SD of triplicate data points.A summary of assay conditions selected from the validation
study as suitable for screening activities is shown in Table 2.
3.4. Assessment of vitro cell toxicity
Data were obtained from HepG2 cells, HepG2 cells plus rS9/
NADPH and HPH which were exposed to 144 drugs, using the
incubation conditions and parameters which are summarised in
Table 2. For each compound a total of 25 parameters were evalu-
ated, which yielded 64 different assay endpoints. These are listed
in Supplementary Table 6. In order to exclude data that could not
be attributed to cell exposure to the drugs, in vitro assay signals
were deﬁned as values that differed from the corresponding
vehicle control value by at least 6 times the standard deviation
of the control value.
Data which summarises the association between individual as-
say endpoints and whether or not these were observed with drugs
that caused DILI is summarised in Supplementary Table 6 and in
Fig. 3a. Although many of the endpoints exhibited high DILI spec-
iﬁcity (>90%), overall their sensitivities were low and only one end-
point exhibited DILI sensitivity of greater than 40%. This was
maximal CM-H2DFFDA fold induction (i.e. ROS formation) in HPH
exposed to the drugs for 24 h, which exhibited DILI sensitivity of
41% and speciﬁcity of 86%. Interestingly, a markedly lower DILI
sensitivity (19%) was observed when the same endpoint and expo-
sure interval was assessed in HepG2 cells (see Supplementary
Table 6).
To explore whether a combination of multiple assay endpoints
could enable improved sensitivity of DILI detection, a scoring algo-
rithm which took account of whether in vitro signals were ob-
served and also the potency of the effect was developed:
 When an endpoint signal was not observed with a test com-
pound at any of the tested concentrations (the maximum tested
concentration was 250 lM), a score of 0 was assigned.
 When a signal was seen only at a relatively high concentration
(i.e. IC50 or EC50 > 79.1 lM) the score for the endpoint was 1.
The threshold of 79.1 lM represents the penultimate tested
concentration; therefore compounds that are only active at
top dose will be excluded using these criteria.mide for 4 h (a–c) or for 24 h (d–f): (a and d) in the absence of ratS9 (rS9)/NADPH; (b
was assessed at 48 h after compound addition to the cells using HCA multiplexed
nti-phospho-Histone-H3). Percent of control (POC) = cell count (compound treated
as fold signal induction or reduction when compared with vehicle controls. Data are
Table 2
Endpoints and incubation times used when screening drugs for in vitro cell toxicity.
Cell type Time of exposure to test compound (h)
4 h 24 h 24 h, followed by 24 h incubation with medium alone 48 h
HepG2 Cell count Cell count Cell count Phospholipid
H2DFFDA H2DFFDA Casapse-3 Neutral Lipid
TMRE TMRE p-Histone H3
Caspase-3 HSP70/72
HepG2 + S9 n.t. n.t Cell count n.t.
Caspase-3
p-Histone H3
HSP70/72
HPH Cell count Cell count n.t. n.t.
H2DFFDA H2DFFDA
TMRE TMRE
Caspase-3
n.t. = Not tested.
Fig. 3. Correlation between all in vitro assay endpoints and DILI. (a) Comparison
between the DILI speciﬁcities and sensitivities of the individual assay endpoints; (b)
cumulative in vitro assay signals caused by drugs which caused DILI in humans (DILI
categories 1, 2 or 3) and by drugs which did not cause DILI (DILI categories 4 or 5).
Table 3
Correlation between the number of in vitro assay signals and DILI caused by the tested
drugs.
Number of assay signals Sens Spec PPR NPR ACC MCC
8 or more 0.36 0.94 0.95 0.33 0.5 0.29
6 or more 0.43 0.83 0.88 0.33 0.53 0.23
4 or more 0.50 0.67 0.82 0.31 0.54 0.14
2 or more 0.73 0.36 0.77 0.31 0.64 0.09
When compiling the statistics, drugs in DILI categories 1, 2 or 3 were considered
true positives and drugs in DILI categories 4 or 5 were considered true negatives.
Sens = sensitivity, Spec = speciﬁcity, PPR = Positive Prediction Rate, NPR = Negative
Prediction Rate, ACC = accuracy, MCC = Matthews coefﬁcient.
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centration (IC50 or EC50 < 79.1 lM), the score was 2.
The concentration of 79.1 lM was selected because it was the
penultimate concentration tested; therefore IC50 or EC50 values
that were lower than this value could be determined with conﬁ-
dence. Since 64 endpoints were evaluated, the maximum cumula-
tive score that might have been caused by any of the drugs was
128.
Drugs that caused DILI exhibited a higher frequency of multiple
in vitro assay endpoints than drugs that did not cause DILI (Fig. 3b).
Furthermore, the DILI speciﬁcity and hence Positive Prediction Rate
(PPR) of the in vitro endpoints improved markedly when higher
numbers of cumulative assay hits were considered. However, this
was accompanied by a progressive reduction in DILI sensitivity
and in Negative Prediction Rate (NPR) (Table 3). Eight or more
cumulative in vitro assay signals were observed with 37 of the108 drugs which caused DILI (sensitivity 34%), but with only one
of the 36 drugs which did not cause DILI (speciﬁcity 97%) (Fig. 3).
The clear ‘‘false positive’’ drug was the anticancer agent mitoxan-
trone, which exhibited a very high number of cumulative assay
hits.
A further analysis was undertaken to determine whether im-
proved sensitivity and speciﬁcity of identiﬁcation of drugs which
caused DILI could be obtained by combination of endpoints that
exhibited highest DILI sensitivities when analysed separately.
Fourteen endpoints exhibited DILI sensitivities of 20% or more
(Fig. 3a). Eleven of these endpoints were obtained from HepG2
cells – rS9/NADPH (two ROS, ﬁve apoptosis, two PLD and two cell
count), one endpoint was from HepG2 cells + rS9/NADPH (apopto-
sis) and two endpoints were from HPH (ROS) (further details are
provided in Supplementary data Table 6). Many of the tested drugs
exhibited multiple signals when these selected endpoints were
considered and the frequency and number of signals was higher
amongst drugs that caused DILI than amongst drugs that did not
(Fig. 4a). However, this approach resulted in a lower sensitivity
of detection of DILI than was evident when all endpoints were as-
sessed, although it did provide improved DILI speciﬁcity (Table 4;
compare with Table 3).3.5. Human plasma exposure to the drugs
Human total and unbound Cmax values were determined from
the scientiﬁc literature for 119 of the 144 drugs and are summa-
rised in Fig. 4b and c (individual values are listed in Supplementary
Table 7), as are the DILI categories of the drugs. Drugs in all DILI
categories exhibited a broad range of human Cmax values. The rect-
angle on the graphs highlights drugs whose total (Fig. 4b) or un-
bound Cmax values exceed 79.1 lM (Fig. 4c), which was the
second highest drug concentration tested in vitro.
Fig. 4. Correlation between selected in vitro endpoints and DILI and between the
maximum and unbound plasma concentrations (free) of drugs and their DILI
categories. (a) Cumulative in vitro assay results obtained using the 14 assay
endpoints where DILI sensitivity exceeded 0.20; (b) reported total Cmax values of
119 of the drugs. (c) Reported unbound Cmax values of 119 of the drugs. The
rectangles on b and c highlight the drugs for which total or free Cmax exceeded
79.1 lM respectively.
Table 4
Correlation between selected in vitro assay signals and DILI caused by the tested
drugs.
Number of assay hits Sens Spec PPR NPV ACC MCC
>8 0.13 0.97 0.93 0.27 0.34 0.14
>6 0.23 0.97 0.96 0.30 0.42 0.23
>4 0.38 0.86 0.89 0.32 0.50 0.22
>2 0.50 0.53 0.76 0.26 0.51 0.02
The data in this analysis are shown in Fig. 4a. Sens = sensitivity, Spec = speciﬁcity,
PPR = Positive Prediction Rate, NPR = Negative Prediction Rate, ACC = accuracy,
MCC = Matthews coefﬁcient.
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To gain further insight into possible associations between the
in vitro assay endpoints and DILI, a hierarchical clustering approachwas used to group the drugs based on the similarity of their assay
proﬁles. This unsupervised analysis revealed seven clusters of com-
pounds, which are illustrated in Fig. 5a, that have similar activity
pattern in the in vitro panel. Clusters 1, 2 and 3 contained 18 drugs,
all of which exhibited numerous in vitro assay signals, albeit with
somewhat different overall proﬁles which distinguished between
the individual clusters, e.g. cluster 2 is categorized by showing
more activity in the 4 h experiments than compounds in other
clusters. Cluster 1 contained 5 drugs which caused DILI (hycan-
thone, quinacrine, sunatinib, dasatinib and amodiaquine) and one
drug which caused transaminitis, but not DILI (mitoxantrone). All
of the 5 drugs in cluster 2 (perhexiline, tamoxifen, chlorpromazine,
amiodarone, ﬂuoxetine, amlodipine and astemizole) and the 5
drugs in cluster 3 (alpidem, celecoxib, triﬂuoperazine, clomipra-
mine and amitryptiline) caused DILI. The 21 drugs in cluster 4
(17 of which caused DILI) and the 15 drugs in cluster 5 (13 of which
caused DILI) caused lower overall frequencies of in vitro signals
than drugs in clusters 1, 2 or 3; however, these drugs exhibited a
relatively high frequency of activated caspase-3 expression, indi-
cating induction of apoptosis. All of the 17 drugs in cluster 6 (16
of which caused DILI) exhibited elevated CM-H2DFFDA staining,
indicating generation of ROS, but very few other signals. Elevated
CM-H2DFFDA staining was also observed with 15 of the 72 drugs
in cluster 7 (21%), which otherwise exhibited relatively few assay
signals and included 45 drugs which caused DILI.
The clustering approach was unable to differentiate between
drugs in DILI severity categories 1, 2 and 3. Drugs which did not
cause DILI (DILI severity categories 4 and 5) were distributed
across clusters 4–7 (Fig. 5b). A statistical analysis of the concor-
dance between the cluster analysis and DILI caused by the drugs
is summarised in Table 5. The best discrimination between drugs
that caused DILI and drugs that did not was obtained when drugs
in clusters 1–6 were compared with drugs in cluster 7. This pro-
vided DILI sensitivity of 58%, speciﬁcity of 75%, a positive predic-
tive rate of 88% and overall accuracy of 63% (Table 5).
It is notable that 18 of the drugs which caused DILI but had low
numbers of assay hits and assigned to cluster 6 and 7, exhibited
high total Cmax values which exceeded 79.1 lM. Furthermore, all
compounds with an unbound Cmax value exceeding 79.1 lM were
in cluster 7 and 5 out of 6 of these compounds had a DILI classiﬁ-
cation between 1 and 3. The high positive predictive rate indicates
that the cluster analysis is well-suited to identify potential DILI
compounds at an early stage with a low risk of discarding clean
compounds. However, it is not able to identify all potential DILI
concerns, especially if the Cmax value will be high.4. Discussion
A high throughput 384-well format was used to investigate the
in vitro effects of 144 drugs on HepG2 cells cultured in the absence
or presence of rat S9 and on cryopreserved HPH. The parameters
assessed were cell number (Hoechst 33342 or DAPI), ROS (CM-
H2DFFDA), mitochondrial membrane potential (TMRE), apoptosis
(activated caspase-3), cell cycle arrest (phospho-Histone-H3), cell
stress response (HSP70/72), phospholipidosis (LipidTOX™ Green
Phospholipid Stain) and neutral lipid accumulation (LipidTOX™
Red Neutral Lipid Stain). Experiments undertaken with selected
validation compounds veriﬁed that robust and reproducible data
could be obtained and that the cell models were appropriate for
detection of compound induced changes in these parameters. The
144 tested drugs were each assigned to one of ﬁve DILI categories,
which took account of information extracted from the scientiﬁc lit-
erature on whether they caused DILI in humans, the severity of the
liver damage and the regulatory outcome. This enabled us to ex-
plore the association between the in vitro data and DILI in man.
7 6 5 4 3  2 1(a)
(b)
Fig. 5. Hierarchical cluster analysis of in vitro cell toxicity data. (a) Unsupervised clustering grouped compounds with a similar activity proﬁle across all assay parameters and
(b) the percentage of drugs in each DILI category within the clusters.
Table 5
Correlation between the outcome from the hierarchical clustering analysis and DILI
caused by the tested drugs.
Cluster Sens Spec PPR NPR ACC
1 0.05 0.97 0.83 0.25 0.28
2 0.06 1.00 1.00 0.26 0.30
3 0.05 1.00 1.00 0.26 0.28
4 0.16 0.89 0.81 0.26 0.34
5 0.12 0.92 0.81 0.26 0.32
6 0.15 0.97 0.94 0.28 0.35
7 0.42 0.25 0.63 0.13 0.38
1 + 2 0.11 0.97 0.92 0.27 0.33
1 + 2 + 3 0.16 0.97 0.94 0.28 0.36
1 + 2 + 3 + 4 0.31 0.86 0.87 0.30 0.45
1 + 2 + 3 + 4 + 5 0.44 0.78 0.85 0.31 0.52
1 + 2 + 3 + 4 + 5 + 6 0.58 0.75 0.88 0.38 0.63
1 + 2 + 3 + 6 0.31 0.94 0.94 0.31 0.47
Sens = sensitivity, Spec = speciﬁcity, PPR = Positive Prediction Rate, NPR = Negative
Prediction Rate, ACC = accuracy.
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iﬁcity but low sensitivity. The endpoint which provided the most
accurate discrimination between drugswhich causedDILI and those
that did notwasmaximal fold induction of CM-H2DFFDA staining in
HPH exposed to test drug for 24 h (41% sensitivity, 86% speciﬁcity).
Other endpoints exhibited lower sensitivity and only 14 endpointsexhibited >20% sensitivity. Improved sensitivitywas obtainedwhen
data from the endpoints was analysed collectively. A cumulative
scoring approach which combined numerical scores for each end-
point, took into accountwhether a signal was observed (i.e. an assay
value different from that in cells exposed to vehicle alone) and
whether the IC50 or EC50 value was at or below a threshold value
of 79.1 lM. When all endpoints were included, DILI speciﬁcity and
hence Positive Predictive Rate (PPR) was improved progressively
as higher numbers of cumulative assay hits were considered. How-
ever, this was accompanied by a progressive reduction in DILI sen-
sitivity and Negative Predictive Rate (NPR). An attempt was made
to improve the DILI sensitivity and speciﬁcity of this approach by
inclusion only of data from the 14 endpoints that exhibitedDILI sen-
sitivity >20%. Although this resulted in slightly lower sensitivity for
the detection of DILI than was evident when all endpoints were as-
sessed, a slight improvement in speciﬁcity was observed.
The most accurate discrimination between DILI and non-DILI
drugs with a reasonable speciﬁcity (>75%), was provided by the
hierarchical clustering approach. Combining drugs in clusters 1–6
provided accuracy of 63%, speciﬁcity of 75% and positive predictive
rate of 88%, plus sensitivity of 58% and negative predictive rate of
38%. This sensitivity is comparable with that reported by Xu
et al. (2008), who assessed the effects of >300 drugs on a range
of endpoints in HPH, but is markedly less than the sensitivity value
of 93% reported by O’Brien et al. (2006) who undertook studies
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reported speciﬁcity values that exceeded 90% for the detection of
DILI, whereas we observed 75% speciﬁcity. O’Brien et al. (2006)
evaluated toxicity to a mixture of industrial chemicals, agrochem-
icals and drugs and tested relatively few compounds that did not
cause DILI, which could explain their increased DILI sensitivity. It
is also conceivable that differences in the cells used, the conditions
used for incubation of the cells with the test compounds and/or the
imaging platforms used could have contributed to the different re-
sults obtained.
Our clustering analysis highlighted that 18 of the 144 drugs (i.e.
drugs in clusters 1, 2 and 3) exhibited signals in many of the in vitro
assays. One of these drugs was mitoxantrone, which is a DNA-reac-
tive agent which intercalates into deoxyribonucleic acid (DNA)
through hydrogen bonding, causes crosslinks and strand breaks
and exerts cytocidal effects in vitro; it is used to treat patients with
several life threatening diseases and has a black box warning for
cardiotoxicity (package insert). Therefore although mitoxantrone
has not been reported to cause DILI and so was considered a ‘‘false
positive’’ in our studies, its observed toxicity to HepG2 cells and
HPH is unsurprising. Furthermore, published work has suggested
that cytotoxicity observed in the HepG2 and THLE cell lines is
not restricted to compounds that cause heptatotoxicity and is also
observed with compounds that cause cardio- and nephro-toxicity
(Benbow et al., 2010; Lin and Will, 2012). Therefore, it is possible
that the utility of the assays described in this study may be broader
than the in vitro prediction of hepatotoxins and that these ap-
proaches may aid in ﬂagging compounds with a high propensity
to cause organ toxicity in general, rather than hepatotoxicity
speciﬁcally.
The in vivo unbound concentration of drugs that we tested ran-
ged widely, from <0.01 lM to >1 mM. We did not attempt to com-
pare these values with the apparent EC50/IC50 values calculated
from our in vitro assay data, as others have done (e.g. O’Brien
et al., 2006; Xu et al., 2008), since such analyses assume that all
of the drugs added to the cells remain free in solution and that
there is no binding to proteins or lipids present in the media or cell.
Since many of the drugs exhibit relatively poor aqueous solubility
and high levels of binding to plasma proteins, it is highly likely that
the unbound concentrations present during the cell toxicity studies
were much lower than the values that we used when estimating
apparent EC50/IC50 values, at least for some of the drugs. It should
also be born in mind that many drugs accumulate within hepato-
cytes in vivo at concentrations which are much higher than those
in the blood compartment, due to carrier mediated transport
across the sinusoidal plasma membrane domain (Grime et al.,
2008), an effect which may not be reproduced accurately when
cells are cultured as monolayers in vitro. Furthermore, our
in vitro toxicity data were obtained in the presence of DMSO vehi-
cle. DMSO causes concentration dependent suppression of several
P450 enzyme activities (Easterbrook et al., 2001) and has antioxi-
dant properties (Sanmartin-Suarez et al., 2011). Therefore further
work will be needed to determine the unbound drug concentra-
tions present in vitro under the conditions we used to assess cell
toxicity, and to explore the relationship between these values
and the peripheral blood unbound concentrations of the drugs in
patients in vivo.
Nevertheless, even if one assumes there was no binding to lip-
ids or proteins in vitro, it is clear that the reported unbound Cmax
values of some of the drugs we tested are similar to or greater than
the maximum concentration evaluated in vitro (250 lM). These in-
cluded numerous drugs which caused DILI and caused few or no
in vitro signals. Therefore evaluation of possible cell toxicity caused
by higher concentrations of these drugs is warranted.
Apart from cyclophosphamide, none of the tested drugs
exhibited markedly potentiated cell toxicity to HepG2 cells in thepresence of rS9 plus an NADPH regenerating system. This approach
has been used by other investigators to demonstrate metabolite
mediated cell toxicity caused by numerous drugs which caused
DILI (Vignati et al., 2005). However, the magnitude of the potenti-
ated toxicity observed in these studies was small. Since P450 en-
zymes exhibit marked variability between species (Fery et al.,
2010; Xie et al., 2013), the Aroclor induced rat S9 fraction may
not be optimal for investigation of drug bioactivation. Data ob-
tained from studies of drug toxicity to cell lines transfected with
human P450s have indicated that, although numerous drugs are
metabolized by these enzymes to toxic metabolites, for most drugs
this results in modest potentiation of toxicity that can be observed
in the absence of P450 dependent metabolism (Gustafsson et al.,
2013; Thompson et al., 2012). It remains to be determined whether
modest effects on toxicity can be detected using the automated
high volume multi-parametric screening approach we used in
our studies.
Overall, our results support the proposal (O’Brien et al., 2006;
Xu et al., 2008) that multi-parametric high content cell toxicity
studies can aid the in vitro detection of drugs that have high pro-
pensity to cause DILI in vivo. If used to support compound proﬁling
during drug discovery, such assays have the potential to aid selec-
tion of drugs with reduced likelihood to cause DILI in humans. In
addition, it is likely that compounds causing toxicity to other or-
gans may also be detected in these assays, therefore any speciﬁcity
for hepatotoxins over compounds toxic to other organs should be
determined in future work. However, due to the increased cost of
running imaging-based assays the value of this approach over tra-
ditional cytotoxicity endpoints must be demonstrated.
The modest DILI sensitivity that we observed indicates that this
approach is not in itself sufﬁcient to detect all potentially hepato-
toxic drugs. The cells tested and the endpoints evaluated address
only some of the many processes which may initiate DILI. Impor-
tant mechanisms that were outside the scope of our analysis in-
clude inhibition of the biliary transporters BSEP and Mrp2
(Dawson et al., 2012; Thompson et al., 2012), and activation of in-
nate and adaptive immune responses (Uetrecht, 2009). The ap-
proaches we have used in the present study may therefore be of
greatest value for prediction of DILI if they are part of a test cascade
which includes in vitro models that also address these other
processes.
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